brinzolamide (Azopt)

1.	Stewart, W C: 2 articles (11/2006 - 09/2004)
2.	Mishima, Hiromu K: 2 articles (07/2005 - 04/2005)
3.	Scott, Haydn: 1 article (06/2008)
4.	Bergamini, Michael V W: 1 article (06/2008)
5.	Brinzolamide Pediatric Study Group: 1 article (06/2008)
6.	Robin, Alan L: 1 article (06/2008)
7.	Woodside, Adrienne M: 1 article (06/2008)
8.	Roarty, John D: 1 article (06/2008)
9.	Kóthy, Péter: 1 article (06/2008)
10.	Vijaya, Lingam: 1 article (06/2008)

Related Diseases

1.	Ocular Hypertension (Glaucoma, Suspect) 10/01/2003 - "This study examines the mechanisms by which brinzolamide reduces intraocular pressure (IOP) in healthy rabbits and in monkeys with unilateral ocular hypertension" 02/01/2000 - "This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension" 01/01/2000 - "A multicenter, double-masked, placebo-controlled, parallel trial was conducted to evaluate the optimal intraocular pressure (IOP)-lowering concentration and ocular tolerability of topically administered brinzolamide (0.3%, 1%, 2%, and 3%) in patients with primary, open-angle glaucoma or ocular hypertension" 01/01/2003 - "Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension." 01/01/2000 - "When administered twice daily, brinzolamide 1% was well tolerated by patients with primary open-angle glaucoma or ocular hypertension." Get all the results and reference details, order at left...
2.	Open-Angle Glaucoma (Glaucoma, Open Angle) 05/01/2004 - "Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients." 02/01/2000 - "This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension" 01/01/2000 - "A multicenter, double-masked, placebo-controlled, parallel trial was conducted to evaluate the optimal intraocular pressure (IOP)-lowering concentration and ocular tolerability of topically administered brinzolamide (0.3%, 1%, 2%, and 3%) in patients with primary, open-angle glaucoma or ocular hypertension" 01/01/2003 - "Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension." 01/01/2001 - "The patients were divided in two groups: group I--included 10 patients (20 eyes) with primary open-angle glaucoma in which suspension Brinzolamide was administrated in monotherapy, and, group II--(16 patients with 30 eyes) with diverse forms of hypertensive glaucomas, that the Brinzolamide was administrated in adjunctive therapy, after the failure of another forms of medication, especially, beta-blockers" Get all the results and reference details, order at left...
3.	Glaucoma 06/01/2008 - "Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial." 01/01/2001 - "The primary objective of this prospective study was to evaluate the efficacy of lowering intraocular pressure, safety and tolerability of Brinzolamide 1% ophthalmic suspension as primary or adjunctive therapy in hypertensive glaucomas" 06/01/2008 - "Brinzolamide was more efficacious for glaucoma associated with systemic or ocular abnormalities and less efficacious for primary congenital glaucoma" 12/01/2005 - "Brinzolamide can be used as the main medication for the treatment of glaucoma." 05/01/2003 - "PATIENTS AND METHODS: n = 15 eyes of 8 normal tension glaucoma patients were subjected to colour Doppler imaging and Langham-OBF (LOBF) before and during a therapy for 3 - 5 weeks with brinzolamide" Get all the results and reference details, order at left...
4.	Pain (Aches) 09/01/2004 - "CONCLUSIONS: This study suggests that subjects treated with dorzolamide suffer more ocular pain upon instillation compared to brinzolamide or placebo" 09/01/2004 - "RESULTS: After chronic dosing, there was a significant difference in ocular pain on the visual analogue scale among the groups at the 10-s postinstillation time point with dorzolamide having the highest level (22.5+/-28.9) compared to brinzolamide (5.0+/-8.7) or placebo (3.2+/-10.4) (P=0.0006)" 05/01/2001 - "The most frequent side effect was ocular pain in the case of 2% dorzolamide and blurred vision in 1% brinzolamide" Get all the results and reference details, order at left...
5.	Cataract (Cataracts) 03/01/2008 - "In clinical trials, brinzolamide 1% has been shown to be able to reduce IOP when administered as monotherapy, adjunctive therapy or after cataract surgery" 03/01/2005 - "CONCLUSION: Both travoprost and brinzolamide significantly lowered IOP after small incision phacoemulsification cataract surgery within the first 24 h without any side effect." 03/01/2005 - "PURPOSE: To evaluate the intraocular pressure (IOP) lowering effect of travoprost and brinzolamide within the first 24 h after phacoemulsification cataract surgery" Get all the results and reference details, order at left...
16 Diseases and 53 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Timolol (Blocadren)
2.	brinzolamide (Azopt)
3.	travoprost (Travatan)
4.	dorzolamide (Trusopt)
5.	brimonidine (Alphagan)
6.	Carbonic Anhydrases (Carbonic Anhydrase)
7.	latanoprost (Xalatan)
8.	Betaxolol (Kerlon)
9.	Retinaldehyde (Retinal)
10.	Glutamic Acid (Glutamate)
36 Drugs and Important Bio-Agents and 44 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Flowmeters
2.	Phacoemulsification
2 Therapies and Procedures and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>